{"6":{"dur":10,"text":">>David Roberts: Perhaps now we can move to\nthe next agenda item, which is the new Cancer"},"16":{"dur":5,"text":"Drugs Fund. This has been here before. It\nis not new news, but we have had the consultation,"},"22":{"dur":4,"text":"and therefore I think the purpose of this\nis to review that consultation and then to"},"26":{"dur":6,"text":"agree the specific way forward, in order that\nwe can give clarity to all stakeholders. Bruce,"},"33":{"dur":1,"text":"I think you are providing the intro on this."},"34":{"dur":5,"text":">>Bruce Keogh: Thanks very much, Chair. I\nwill just start by giving a little bit of"},"40":{"dur":8,"text":"context. Improving cancer care is an absolute\npriority for NHS England, and the reason for"},"48":{"dur":6,"text":"that is that it touches the lives and families\nof so many citizens of this country."},"55":{"dur":6,"text":"Globally and in the NHS, we have made a lot\nof progress over the last decade, but that"},"61":{"dur":5,"text":"is dependent on access to the newest treatments\nand the most effective treatments, as quickly"},"67":{"dur":1,"text":"as possible."},"69":{"dur":7,"text":"So improving the Cancer Drugs Fund is one\nof our commitments. We have discussed this"},"76":{"dur":5,"text":"at the Board in 2015 and, indeed, since then\nwe have had a National Audit Office report,"},"81":{"dur":8,"text":"a Public Accounts Committee report and a Cancer\nTaskforce led by Harpal Kumar, all of which"},"89":{"dur":3,"text":"suggested that we needed to improve the Cancer\nDrugs Fund."},"93":{"dur":6,"text":"So in late 2014 I started discussions with\nthe charities, the Association of British"},"99":{"dur":6,"text":"Pharmaceutical Industries, the Department\nof Health, NICE, the MHRA and others so that"},"106":{"dur":6,"text":"we could start to think of a way forward for\nthe Cancer Drugs Fund."},"112":{"dur":5,"text":"We got to a point of formal consultation in\nNovember 2015, and that consultation closed"},"118":{"dur":9,"text":"on 11 February. During that time we had 286\nresponses, variably from the pharmaceutical"},"128":{"dur":5,"text":"industry, patient groups and charities, people\nworking in the National Health Service and"},"133":{"dur":1,"text":"individuals."},"135":{"dur":9,"text":"Of course, we need time to fully process some\nof those, but there were three main themes"},"144":{"dur":4,"text":"that seem to have emerged from the consultation.\nThe first is that there is general support"},"148":{"dur":7,"text":"for a managed access process with clear entry\nand exit criteria into the Cancer Drugs Fund."},"156":{"dur":6,"text":"The second is that there was a need for much\ngreater clarity on the operational detail,"},"162":{"dur":6,"text":"and in particular for the mechanisms of financial\ncontrol. Thirdly, people wanted to be reassured"},"169":{"dur":6,"text":"that we had clear details of transition to\nthe new Cancer Drugs Fund."},"175":{"dur":6,"text":"Interestingly, and not surprisingly, there\nwere some contrasting views. People asked"},"182":{"dur":4,"text":"whether the new Cancer Drugs Fund would lead\nto more or less access to cancer drugs, and"},"187":{"dur":6,"text":"I will come back to that. There were also\nquestions raised about whether cancer should"},"194":{"dur":6,"text":"have a special status, over and above treatments\nfor other conditions."},"200":{"dur":7,"text":"The paper which is in front of you describes\nour response to the consultation. I think"},"207":{"dur":7,"text":"I would like to start by drawing people's\nattention to the front page of the paper,"},"214":{"dur":5,"text":"where we quite clearly state that, for patients,\nthe new, improved version of the Cancer Drugs"},"220":{"dur":6,"text":"Fund will help provide faster access to the\nmost promising cancer treatments for our patients."},"226":{"dur":6,"text":"Secondly, for taxpayers, the new Cancer Drugs\nFund will drive stronger value for money in"},"232":{"dur":9,"text":"drugs expenditure. Finally, for drug companies\nwho are willing to price their products appropriately,"},"242":{"dur":7,"text":"the Cancer Drugs Fund offers a new fast-track\nroute to NHS funding for drugs at the point"},"249":{"dur":4,"text":"of market authorisation."},"254":{"dur":6,"text":"The key elements of a managed access process\nare these, and I will go through them at a"},"260":{"dur":5,"text":"relatively high level. Firstly, all new cancer\ndrugs will be referred to NICE for assessment."},"265":{"dur":3,"text":"This is a new development."},"269":{"dur":6,"text":"Secondly, the assessment will not simply be\nyes or no; there will be an option for a maybe"},"276":{"dur":6,"text":"when there is some level of uncertainty about\nthe value proposition or effectiveness of"},"282":{"dur":3,"text":"a given drug."},"286":{"dur":7,"text":"Those drugs or indications which are regarded\nas a maybe will become candidates for the"},"293":{"dur":7,"text":"new Cancer Drugs Fund, and entry into that\nwill be approved by a joint NHS\/NICE investment"},"300":{"dur":7,"text":"group or committee. Once a drug has spent\ntime in the Cancer Drugs Fund and the uncertainty"},"308":{"dur":8,"text":"has been resolved or enough data has been\ncollected, NICE will perform a final appraisal"},"316":{"dur":7,"text":"and opine yes or no with respect to whether\nthat drug should move into routine commissioning."},"323":{"dur":4,"text":"The end result of this means that flow through\nthe Cancer Drugs Fund, because there are clear"},"328":{"dur":10,"text":"entry and exit criteria, will be greater and\nmore flexible than it is at the moment. However,"},"338":{"dur":6,"text":"this does require NICE to work at a greater\nspeed than it has done in the past."},"345":{"dur":6,"text":"To that end, it will produce draft guidance\non drugs before marketing authorisation, with"},"351":{"dur":8,"text":"the aim of producing final guidance within\n90 days of marketing authorisation. That will"},"360":{"dur":6,"text":"require additional resourcing, and we have\nreceived assurance from NICE that they will"},"366":{"dur":8,"text":"be able to develop the capacity and capability\nto meet those particular challenges."},"375":{"dur":9,"text":"The new Cancer Drugs Fund will go live on\n1st July this year, not on 1st April. This"},"384":{"dur":9,"text":"will give us time to resolve a number of issues.\nFirstly, the practical aspects of NICE publishing"},"393":{"dur":4,"text":"initial recommendations prior to marketing\nauthorisation."},"397":{"dur":8,"text":"Secondly, to enable us to address the risk\nof funding ineffective treatments during transition."},"406":{"dur":8,"text":"Thirdly, how we can treat rare cancers and\noff-label drugs fairly. It is likely that"},"415":{"dur":7,"text":"those particular drug and indication combinations\nwill be associated with greater uncertainty,"},"423":{"dur":4,"text":"so that is likely to give them much greater\naccess into the Cancer Drugs Fund, which is"},"428":{"dur":4,"text":"different from the position that we find ourselves\nin at the moment where they are often crowded"},"432":{"dur":5,"text":"out by more expensive drugs for more common\nconditions."},"437":{"dur":9,"text":"Finally, it will give us time to resolve the\nissue of whether we simply keep drugs in the"},"447":{"dur":7,"text":"fund long enough to resolve the uncertainty,\nor whether we aim to keep drugs in the fund"},"455":{"dur":5,"text":"in a way that gives maximum access to maximum\npatients. I would refer people to the third"},"460":{"dur":6,"text":"bullet point at paragraph 17 for that particular\nissue."},"466":{"dur":7,"text":"So on 1 April this year we will close the\ncurrent Cancer Drugs Fund, but roll drugs"},"474":{"dur":7,"text":"over. Drugs that are in the Cancer Drugs Fund\nwill remain in it until they have been through"},"482":{"dur":11,"text":"a final appraisal process by NICE. We also\nneed to sort out transitional funding arrangements."},"493":{"dur":5,"text":"Those will be delegated, as you will see towards\nthe end of the paper, to the Chief Executive,"},"499":{"dur":8,"text":"the Chief Financial Officer and myself. We\nare clear that we will anticipate seeing reimbursement"},"507":{"dur":24,"text":"for these drugs \nat or below the rates which are in place in\nMarch 2016. We also need to ensure that we"},"532":{"dur":6,"text":"keep the new Cancer Drugs Fund within a fixed\nbudget of \u00a3340 million."},"539":{"dur":7,"text":"The methodology for controlling that expenditure\nhas been and may be described by the Chief"},"547":{"dur":7,"text":"Financial Officer. So it seems to me that\nthe new operating model will remove some level"},"554":{"dur":2,"text":"of uncertainty which currently exists."},"557":{"dur":5,"text":"It will ensure that we are able to balance\nthe budget, and it will give patients clarity"},"562":{"dur":5,"text":"about the status of any given drug or drug\ncombinations much sooner than the current"},"568":{"dur":2,"text":"Cancer Drugs Fund does. Thank you."},"570":{"dur":3,"text":">>David Roberts: Simon, anything you want\nto add to this?"},"574":{"dur":5,"text":">>Simon Stevens: No. I think Bruce summarised\nit well. This is the substance of the discussion"},"580":{"dur":4,"text":"we had very extensively prior to going out\nto consultation, with some important adjustments"},"584":{"dur":2,"text":"made in the light of consultation."},"586":{"dur":3,"text":">>David Roberts: Okay, great. So, questions.\nVictor."},"589":{"dur":7,"text":">>Victor Adebowale: Just to be clear, will\nevery patient getting drugs under the current"},"597":{"dur":5,"text":"fund continue to get drugs under the new regime?"},"603":{"dur":5,"text":">>Bruce Keogh: Just to be clear, the answer\nis yes."},"608":{"dur":0,"text":">>David Roberts: Unequivocally?"},"609":{"dur":1,"text":">>Bruce Keogh: Absolutely, Chair."},"610":{"dur":1,"text":">>David Roberts: Good. Okay. John."},"612":{"dur":3,"text":">>John Burn: We all knew, when the Cancer\nDrugs Fund was introduced that it was something"},"615":{"dur":5,"text":"of an emergency measure and an emergency treatment,\nso this is actually a really impressive adaptation"},"621":{"dur":6,"text":"and evolution of that into something that\nis much more adaptable to the needs of now."},"627":{"dur":3,"text":"You said at the beginning that one of the\ncriticisms was that it still has the word"},"631":{"dur":5,"text":"'cancer' on the front, and it is only one\nclass of disease, albeit one of our most pressing"},"636":{"dur":4,"text":"ones. Noel and I sit on the accelerated access\nreview, which is looking at the broader picture"},"641":{"dur":4,"text":"of how we get new, innovative treatments into\nthe Health Service."},"645":{"dur":6,"text":"Can you just maybe connect those two together?\nHow does the accelerated access review connect"},"652":{"dur":4,"text":"to this process? Is this informing that process,\nor will that process inform the further evolution"},"656":{"dur":1,"text":"of the Cancer Drugs Fund?"},"658":{"dur":6,"text":">>Bruce Keogh: I think the Cancer Drugs Fund\nwill inform the accelerated access review."},"664":{"dur":7,"text":"In May last year, I wrote to George Freeman\nindicating that we needed to link the two"},"672":{"dur":1,"text":"processes."},"673":{"dur":7,"text":"I think the issue which will influence that\nis the speed at which the accelerated access"},"681":{"dur":7,"text":"review can come to its final conclusions,\nbut it is quite clear from their interim report"},"688":{"dur":2,"text":"that the two are pretty well aligned."},"692":{"dur":5,"text":">>Noel Gordon: May I just say in passing,\nChairman, that this paper came through specialised"},"697":{"dur":6,"text":"commissioning yesterday? Or course Sir John,\nwho is a real cancer expert, Margaret Casely"},"704":{"dur":6,"text":"Hayford and myself put it under the expected\nchallenge and test of an assurance process."},"710":{"dur":5,"text":"So I wanted to make the point that this has\nalready, in a sense, been battle-tested as"},"716":{"dur":2,"text":"far as our assurance process is concerned."},"718":{"dur":10,"text":"Bruce, the CDF as it is currently constituted\nworked for what I might call common conditions."},"729":{"dur":7,"text":"How is it going to help with patients suffering\nfrom rarer cancer conditions?"},"736":{"dur":5,"text":">>Bruce Keogh: The way I see it working is\nthat the new Cancer Drugs Fund is largely"},"742":{"dur":10,"text":"there to resolve issues of uncertainty related\nto the effectiveness of different drugs. In"},"752":{"dur":5,"text":"the past, drugs for rare cancers have not\nbeen appraised by NICE."},"758":{"dur":4,"text":"They will be appraised by NICE as part of\nthe new process. I think that will expose"},"762":{"dur":5,"text":"that, in many cases, there are degrees of\nuncertainty, which I think is likely to lead"},"767":{"dur":6,"text":"to much greater and easier access for those\nparticular drugs into the Cancer Drugs Fund."},"774":{"dur":13,"text":">>Moira Gibb: Bruce, this is not simple. It\nis often talked about in very simplistic terms,"},"787":{"dur":7,"text":"though, in the media, so I would like something\nvery simple: how is this better for patients"},"794":{"dur":2,"text":"than what we have now?"},"796":{"dur":9,"text":">>Bruce Keogh: I think it will provide faster\naccess for patients, and I think that is really"},"806":{"dur":8,"text":"important. I think it will also bring clarity\nas to which drugs are the most effective drugs,"},"814":{"dur":5,"text":"sooner than we know at the moment. I think\nthose are probably the two main things."},"820":{"dur":2,"text":">>Moira Gibb: Thank you."},"823":{"dur":8,"text":">>Bruce Keogh: May I just add one other point\nthat is quite important here? The current"},"831":{"dur":7,"text":"Cancer Drugs Fund is full. What we have with\nthe new Cancer Drugs Fund is a system that"},"839":{"dur":3,"text":"is much more fluid and much more flexible."},"842":{"dur":10,"text":"We have clear entry and exit criteria, so\nwe can bring new drugs in with greater ease,"},"852":{"dur":4,"text":"if you like, because we can get ineffective\ndrugs out, or drugs where the uncertainty"},"857":{"dur":5,"text":"is resolved, or drugs which move into routine\ncommissioning earlier, in a way that we cannot"},"862":{"dur":3,"text":"do quite as easily at the moment."},"865":{"dur":7,"text":">>Noel Gordon: Bruce, you mentioned in your\nintroduction the consultation process and"},"872":{"dur":2,"text":"the 286 responses received."},"875":{"dur":6,"text":"I was interested, as I was reading through\nthe additional papers that you provided here,"},"881":{"dur":8,"text":"that of the overall number of respondents\nsomething like 34% declared having received"},"890":{"dur":7,"text":"payment from drug companies and, a sub-category\nwithin that overall total being patients'"},"897":{"dur":8,"text":"and voluntary groups, 81% declared they had\nreceived drug company funding."},"906":{"dur":5,"text":"Does that concern you in any way, particularly\nwith reference to our sunlight disclosure"},"911":{"dur":0,"text":"programme?"},"912":{"dur":6,"text":">>Bruce Keogh: I think there are two things\nabout that. Firstly, you would expect a number"},"919":{"dur":7,"text":"of the respondents to have interests in the\npharmaceutical industry, but the second thing"},"926":{"dur":5,"text":"- and this is the most important point - is\nthat people have declared it."},"931":{"dur":6,"text":"I think that is really important, because\nthat brings clarity to any potential conflicts"},"938":{"dur":4,"text":"of interest or views that people might express."},"943":{"dur":9,"text":">>David Roberts: A couple of questions from\nme, if I may, Bruce. There was some suggestion"},"952":{"dur":6,"text":"that a number of drugs - quite a significant\nproportion of the drugs - currently in the"},"958":{"dur":7,"text":"CDF will not make it through the NICE evaluation\nor make it into routine commissioning."},"966":{"dur":7,"text":"I just wonder what we think about that, and\nwhether you would agree with some of the external"},"974":{"dur":5,"text":"reporting that has been done on this?"},"979":{"dur":6,"text":">>Bruce Keogh: We function in a tax-funded\nNational Health Service. We have an obligation,"},"986":{"dur":5,"text":"I think, to get the best value for money for\ntaxpayers, who are also our patients."},"991":{"dur":5,"text":"It is quite a - I was going to say it is a\nsimple formula, but it is not. The formula"},"996":{"dur":7,"text":"which is applied is: how effective is a drug,\nand how much does it cost? Now, the efficacy"},"1003":{"dur":1,"text":"is pretty fixed."},"1004":{"dur":4,"text":"There is one component of that formula which\nis under the control of the pharmaceutical"},"1009":{"dur":6,"text":"companies, and that is the cost of the drug.\nBy influencing the cost of the drug, you can"},"1016":{"dur":5,"text":"influence the likelihood of that drug entering\nroutine commissioning."},"1021":{"dur":5,"text":">>David Roberts: So we do not go into this\nwith any sort of firm, fixed view on this?"},"1027":{"dur":4,"text":"These are things that are still open for discussion\nat an appropriate time?"},"1032":{"dur":1,"text":">>Bruce Keogh: Exactly."},"1033":{"dur":6,"text":">>David Roberts: Good. Then the second thing\nis, within the consultation as I read it,"},"1040":{"dur":11,"text":"one of the most significant areas of concern\nis about the capacity and timeliness within"},"1051":{"dur":8,"text":"NICE to be able to do these reviews, which\nare intense, time-consuming, difficult and"},"1060":{"dur":5,"text":"I think it would be appropriate for us to\nunderstand what assurances and what perspective"},"1065":{"dur":4,"text":"we may have on that, given it was one of the\nmost important aspects of the consultation?"},"1070":{"dur":3,"text":">>Bruce Keogh: Well, the first thing I would\nsay is I think it has been a very legitimate"},"1073":{"dur":5,"text":"concern that people have expressed, and that\nwill have come from many different quarters,"},"1078":{"dur":4,"text":"not least of all patients who have to wait."},"1083":{"dur":7,"text":"So there are two things. Firstly, NICE needs\nto do more work and have greater capability"},"1091":{"dur":5,"text":"and capacity, and that requires resourcing,\nwhich Paul may want to say something about."},"1096":{"dur":5,"text":"However, the second thing - and this is the\nimportant thing - is that we have received"},"1101":{"dur":6,"text":"assurance from NICE that, with the appropriate\nresourcing, they can put that capability and"},"1108":{"dur":1,"text":"capacity in place."},"1109":{"dur":5,"text":">>David Roberts: I understand their board\nis discussing this fairly soon, is that right?"},"1114":{"dur":1,"text":">>Bruce Keogh: Yes. I think it is 17th March."},"1116":{"dur":6,"text":">>David Roberts: Okay. Paul, you were nicely\nset up by your friend. Is there anything that"},"1122":{"dur":0,"text":"you would like to add?"},"1123":{"dur":3,"text":">>Paul Baumann: Set up as usual. I think the\nassurances from NICE are the important part"},"1127":{"dur":5,"text":"of that. They have shared with us their very\nspecific resourcing plans around this, which"},"1133":{"dur":4,"text":"obviously are predicated on the forward pipeline\nthat we can see, and indeed the transitional"},"1137":{"dur":1,"text":"pipeline that we have."},"1139":{"dur":4,"text":"So I am very comfortable that they have considered\nthe correct volume of drugs, as far as we"},"1143":{"dur":3,"text":"can see that. They have worked out what the\nresource is that they need to live to the"},"1147":{"dur":5,"text":"standards that have been set in this. So I\nsee no reason for the Board to doubt the assurances"},"1152":{"dur":1,"text":"that we have been given."},"1154":{"dur":4,"text":">>David Roberts: Therefore, Bruce, from a\nclinical perspective you are comfortable that"},"1158":{"dur":4,"text":"this is the best solution for the way forward,\nfor patients in particular?"},"1162":{"dur":7,"text":">>Bruce Keogh: Yes, I am. I think this has\nbeen a comprehensive, complex process. Some"},"1170":{"dur":8,"text":"of the discussions have inevitably been difficult.\nHowever, I think there is a consensus view,"},"1178":{"dur":6,"text":"certainly among clinical colleagues, that\nwe have moved the dial and moved things forward."},"1184":{"dur":4,"text":">>David Roberts: Paul, you are comfortable\nfrom a financial perspective as well that"},"1188":{"dur":2,"text":"this is the best alternative we can come up\nwith?"},"1190":{"dur":1,"text":">>Paul Baumann: It is."},"1192":{"dur":4,"text":">>David Roberts: You are comfortable, Noel,\nthat from SpecCom yesterday you gave this"},"1196":{"dur":5,"text":"a good working over, and the consultation\nhas been appropriately considered?"},"1201":{"dur":5,"text":">>Noel Gordon: Yes. From both a design and\nimplementation perspective, I think we performed"},"1206":{"dur":2,"text":"a pretty rigorous assurance process yesterday."},"1209":{"dur":7,"text":">>David Roberts: Okay. Any other final questions\nor comments? Simon, anything you would add?"},"1216":{"dur":6,"text":">>Simon Stevens: No. Just to underline, we\nchartered an independent cancer taskforce"},"1223":{"dur":5,"text":"led by Sir Harpal Kumar, the chief executive\nof Cancer Research UK. Their clear recommendation"},"1228":{"dur":4,"text":"to us was to do what we are proposing this\nafternoon."},"1233":{"dur":8,"text":"Secondly, we have had a National Audit Office\nreview of the Cancer Drugs Fund Mark I, and"},"1241":{"dur":6,"text":"it clearly draws attention to the need to\nchange the way the CDF works. Thirdly, that"},"1248":{"dur":7,"text":"case was not only supported but accentuated\nby the Public Accounts Committee of the House"},"1255":{"dur":3,"text":"of Commons, who produced a report to that\neffect as well."},"1258":{"dur":6,"text":"So I think a combination of our cancer taskforce,\nthe National Audit Office in respect of the"},"1265":{"dur":6,"text":"good use of public resources, and Parliament\nthrough the PAC: this is going with the grain"},"1271":{"dur":4,"text":"of what people see as the sensible evolution\nof the Cancer Drugs Fund."},"1276":{"dur":10,"text":">>David Roberts: Thank you. So now, I think,\nif there are no other questions or comments,"},"1286":{"dur":8,"text":"there are a series of recommendations and\nproposals that are made in paragraph 31. I"},"1294":{"dur":4,"text":"am not going to go through and read them all\nin individual glory, but can I take it from"},"1299":{"dur":6,"text":"our conversation that the Board is happy to\napprove the recommendations as set out in"},"1305":{"dur":4,"text":"the paper? Thank you very much."},"1309":{"dur":5,"text":"Bruce, I would like to say to Paul, and indeed\nto John, who is sitting next to you, that"},"1315":{"dur":6,"text":"this has been a considerable effort on all\npersons, and therefore please thank your teams"},"1321":{"dur":5,"text":"on behalf of this Board for their professionalism,\ntheir diligence and their effort and commitment"},"1327":{"dur":4,"text":"to what is a very important subject. Thank\nyou."}}